Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Apogee Therapeutics Highlights APG333 Phase 1 Results Supporting Combination Development With APG777 For Respiratory Diseases

Author: Benzinga Newsdesk | November 10, 2025 07:13am
  • Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing
  • Results support development of a quarterly or less frequently dosed co-formulation of APG273 (APG777+APG333) for respiratory indications
  • APG333 was well tolerated across all cohorts with doses of up to 1,000 mg


 

Posted In: APGE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist